09622815

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1613sxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS	4	Jul 15	Data from 1960-1976 added to RDISCLOSURE
NEWS	5	Jul 21	Identification of STN records implemented
NEWS	6	Jul 21	Polymer class term count added to REGISTRY
NEWS	7	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	8	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	9	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	10	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS	11	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS	12	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS	13	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS	14	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	15	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	16	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS	17	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	18	SEP 22	DIPPR file reloaded
NEWS	19	SEP 25	INPADOC: Legal Status data to be reloaded
NEWS	20	SEP 29	DISSABS now available on STN

NEWS EXPRESS	OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:31:39 ON 06 OCT 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:32:13 ON 06 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 OCT 2003 HIGHEST RN 598296-84-5
DICTIONARY FILE UPDATES: 3 OCT 2003 HIGHEST RN 598296-84-5

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09622815.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 09:32:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     90 TO ITERATE

100.0% PROCESSED      90 ITERATIONS                                2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1231 TO     2369
PROJECTED ANSWERS:               2 TO      124

L2             2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 09:32:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   1965 TO ITERATE

100.0% PROCESSED    1965 ITERATIONS                              30 ANSWERS
SEARCH TIME: 00.00.01

L3            30 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   148.15     148.36

FILE 'CAPLUS' ENTERED AT 09:32:55 ON 06 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 6 Oct 2003 VOL 139 ISS 15
FILE LAST UPDATED: 5 Oct 2003 (20031005/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3 full
L4 21 L3

=> d l4 1-21 ibib abs hitstr

L4 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:491233 CAPLUS
DOCUMENT NUMBER: 139:69413
TITLE: Preparation of N-carbacycle monosubstituted indolocarbazoles for therapeutic use as protein kinase inhibitors
INVENTOR(S): Sahagun-Krause, Heidi; Thillaye Du Boullay, Olivier; Thillaye Du Boullay, Valerie; Casiraghi, Laura; Seneci, Pierfausto; Klafki, Hans-Wolfgang; Braxmeier, Tobias; Mueller, Silvia; Froehner, Wolfgang; Monse, Barbara; Gordon, Sandra; Roder, Hanno
PATENT ASSIGNEE(S): Nad Ag, Germany
SOURCE: PCT Int. Appl., 153 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051887	A1	20030626	WO 2002-EP13753	20021204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10161940	A1	20030703	DE 2001-10161940	20011217

PRIORITY APPLN. INFO.: DE 2001-10161940 A 20011217
OTHER SOURCE(S): MARPAT 139:69413
GI



I



II

AB N-(carbacyclyl)-indolocarbazoles, such as I [R = substituted or unsubstituted 5 or 6 membered carbacyclyl; R3, R4 = H, halogen, alkyl, carboxy, carboxamide, amino, alkoxy, etc.], were prepd. as protein kinase inhibitors which are useful for the treatment of non-insulin dependent diabetes mellitus, acute stroke and other neurotraumatic injuries, malignant diseases, and neurodegenerative diseases, such as Alzheimer's disease. Thus, NAD 006 (II) was prepd. via a multistep synthetic sequence starting from cyclopentadiene, 1H-indole-3-acetonitrile and 2-indolone. The prepd. staurosporine analogs were assayed for inhibition of extracellular signal regulated kinase 2, protein kinase A, protein kinase C and glycogen synthase kinase 3.beta..

IT **287965-04-2P 551000-28-3P 551000-37-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-(carbacyclyl)-indolocarbazoles for therapeutic use as protein kinase inhibitors)

RN 287965-04-2 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-bis(5-fluoro-1H-indol-3-yl)-1-methyl- (9CI) (CA INDEX NAME)



RN 551000-28-3 CAPLUS
CN 2,5-Pyrrolidinedione, 3-(5-bromo-1H-indol-3-yl)-4-(1H-indol-3-yl)-1-methyl- (9CI) (CA INDEX NAME)



RN 551000-37-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-bis(5-methoxy-1H-indol-3-yl)-1-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:674531 CAPLUS
DOCUMENT NUMBER: 138:89601
TITLE: Synthesis, and cytotoxic activity of Nind-alkoxy derivatives of antibiotic arcyriarubin and dechloro-rebeccamycin aglycon
AUTHOR(S): Lakatosh, S. A.; Balzarini, J.; Andrei, G.; Snoeck, R.; De Clercq, E.; Preobrazhenskaya, M. N.
CORPORATE SOURCE: G. F. Gause Institute of New Antibiotics, Russian Academy of Medical Sciences, Moscow, 119021, Russia
SOURCE: Journal of Antibiotics (2002), 55(8), 768-773
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:89601
AB N-alkoxyindole derivs. of arcyriarubin and dechloro-rebeccamycin aglycon were prepd. The cytotoxicity of the derivs. was detd. in three cancer cell lines.

IT **238734-45-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn of N-alkoxyindole derivs. of arcyriarubin and dechloro-rebeccamycin aglycon from indole and N-methyl-2,3-dibromomaleimide and evaluation of their cytotoxic activity)
RN 238734-45-7 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:701229 CAPLUS
DOCUMENT NUMBER: 134:29632
TITLE: Regio-controlled Synthesis of the Antitumor Antibiotic AT2433-A1
AUTHOR(S): Chisholm, John D.; Van Vranken, David L.
CORPORATE SOURCE: Department of Chemistry, University of California, Irvine, CA, 92697, USA
SOURCE: Journal of Organic Chemistry (2000), 65(22), 7541-7553
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:29632
AB The indolo[2,3-a]carbazole glycosides are potent antitumor antibiotics currently undergoing clin. trials for the treatment of numerous types of cancer. AT2433-A1 is the most complex member of this family of compds. possessing a unique disaccharide with a sensitive aminodeoxy sugar and an unsym. aglycon. The synthesis of this natural product requires a method for glycosylation that sets the stereochem. of the anomeric center and the regiochem. of the aglycon. These goals were accomplished by carrying out the Mannich cyclization of a bis-3,4-(3-indolyl)succinimide to give a key class of indoline intermediates that could be glycosylated stereoselectively with complex carbohydrates without hydroxyl protection or activation. The regiochem. of the Mannich cyclization was precisely controlled by choosing between kinetic or thermodn. conditions. This strategy culminated in the first synthesis of the antitumor antibiotic AT2433-A1.
IT **137467-08-4P 222632-24-8P 309758-01-8P 309758-18-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(regiocontrolled synthesis of the antitumor antibiotic AT2433-A1)

RN 137467-08-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 222632-24-8 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-1-methyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 309758-01-8 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-1-methyl-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 309758-18-7 CAPLUS
CN 2,5-Pyrrolidinedione, 3-(7-chloro-1H-indol-3-yl)-4-(1H-indol-3-yl)-1-

methyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:573789 CAPLUS
DOCUMENT NUMBER: 133:177094
TITLE: Preparation of 3,4-di(3-indolyl)pyrrole derivatives as cell death (apoptosis) inhibitors
INVENTOR(S): Asakai, Rei; Sodeoka, Mikiko; Katoh, Miho; Fujita, Mikako
PATENT ASSIGNEE(S): Sagami Chemical Research Center, Japan
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047575	A1	20000817	WO 2000-JP675	20000208
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000023277	A5	20000829	AU 2000-23277	20000208
EP 1152002	A1	20011107	EP 2000-902138	20000208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6589977	B1	20030708	US 2001-890827	20010806

PRIORITY APPLN. INFO.: JP 1999-31036 A 19990209
WO 2000-JP675 W 20000208

OTHER SOURCE(S): MARPAT 133:177094
GI



I

AB Bisindolylpyrrole derivs. represented by general formula (I; R1, R2 = H, (un)substituted alkyl, alkenyl, alkynyl, aryl, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, alkylthiocarbonyl, arylthiocarbonyl, CONH2, aminocarbonyloxy, alkylsulfonyl, arylsulfonyl, alkoxy, or aryloxy, HO; R4, R5 = H, (un)substituted alkyl, alkenyl, alkynyl, aryl, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, alkoxycarbonyloxy, aryloxycabonyloxy, alkylthiocarbonyl, arylthiocarbonyl, CONH2, aminocarbonyloxy, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl, alkoxy, aryloxy, alkylthio, or arylthio, HO, CO2H, SO3H, cyano, NO2, (un)substituted NH2, halo; R1 and R2, R1 and R3, R2 and R4, R3 and R6, R4 and R6, R5 and R6, two R3, or two R4 optionally from (un)substituted hydrocarbon chain optionally contg. hetero atoms; R6 = H, (un)substituted alkyl, alkenyl, aryl, acyl, aryloxy, aryloxycarbonyl, aryloxycarbonyloxy, alkylthiocarbonyl, arylthiocarbonyl, CONH2, aminocarbonyloxy, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl, alkoxy, aryloxy, alkylthio, or arylthio, HO, CO2H, SO3H, cyano, (un)substituted NH2, halo) are prepd. These compds. are useful in inhibiting cell death and expected as being useful as preventives and remedies for the progress of various diseases in the progress and worsening of which cell death participates, e.g. (1) neurodegenerative diseases such as Alzheimer's disease, spinal muscular atrophy (SAM), amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's disease, pigmentary degeneration of the retina, glaucoma, and cerebellum degeneration, (2) new born jaundice, (3) muscular dystrophy, (4) cerebral ischemia or delayed neuron death following cerebral ischemia, (5) myocardial disorders/apoptosis in ischemic heart diseases, viral myocarditis, autoimmune myocarditis, cardiac hypertrophy, heart failure or right ventricular myocardial disease due to arrhythmia, (6) AIDS by inhibiting excessive apoptosis of T cells, (7) dermatitis, hair loss, and graft-vs.-host reaction, (8) disorders due to radiation or drugs, (9) septicemia, (10) myelodysplasty, (11) insulin-dependent diabetes, and (12) failure of transplant organ, tissue or cell function during transplant of organs, tissues, or cells. They are also useful as cell/tissue/organ preservatives. Thus, 9.36 mL 0.95 M ethylmagnesium bromide soln. was added to 1.0 g 2-methylindole in THF and stirred at 40.degree. for 45 min, followed by adding 500 mg 2,3-dibromomaleimide, and the resulting mixt. was refluxed for 3 h to give 62.4% N-methyl-2,3-bis(2-methyl-1H-indol-2-yl)maleimide (II). II (50 mg) was dissolved in 2 mL THF, followed by slowly adding 0.58 mL 0.94 M diisobutylaluminum hydride under ice-cooling, and the resulting mixt. was stirred at room temp. for 4 h to give 40.7% N-methyl-3,4-di(2-methyl-3-indolyl)pyrrole (III). III showed min. inhibitory concn. of 0.03 .mu.M fro inhibiting sodium nitroprusside-induced apoptosis of porcine ovarian granulosa cells (POGC).

IT **115684-55-4P 238734-45-7P 287964-95-8P 287964-98-1P 287965-00-8P 287965-04-2P**

287965-06-4P 287965-09-7P 287965-11-1P
287965-16-6P 287965-18-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 3,4-di(3-indolyl)pyrrole derivs. as apoptosis inhibitors for treatment or prevention of diseases)

RN 115684-55-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)





RN 238734-45-7 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-1-methyl- (9CI) (CA INDEX NAME)



RN 287964-95-8 CAPLUS
CN 2,5-Pyrrolidinedione, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1-methyl- (9CI) (CA INDEX NAME)



RN 287964-98-1 CAPLUS
CN 2,5-Pyrrolidinedione, 3-(1H-indol-3-yl)-1-methyl-4-(1-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



RN 287965-00-8 CAPLUS
CN 2,5-Pyrrolidinedione, 1-methyl-3,4-bis(1-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



RN 287965-04-2 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-bis(5-fluoro-1H-indol-3-yl)-1-methyl- (9CI) (CA INDEX NAME)



RN 287965-06-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-bis(5-methoxy-1H-indol-3-yl)-1-methyl- (9CI) (CA INDEX NAME)



RN 287965-09-7 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-bis(5-methoxy-1-methyl-1H-indol-3-yl)-1-methyl- (9CI) (CA INDEX NAME)



RN 287965-11-1 CAPLUS
CN 2,5-Pyrrolidinedione, 1-methyl-3,4-bis(5-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



RN 287965-16-6 CAPLUS
CN 2,5-Pyrrolidinedione, 3-(1,5-dimethyl-1H-indol-3-yl)-1-methyl-4-(5-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



RN 287965-18-8 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-1-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:553874 CAPLUS
DOCUMENT NUMBER: 133:310045
TITLE: Coupling reactions of indole-3-acetic acid derivatives. Synthesis of arcyriaflavin A
AUTHOR(S): Bergman, Jan; Koch, Eva; Pelcman, Benjamin
CORPORATE SOURCE: Karolinska Institute, Department of Biosciences of

09622815

Novum, Sweden and Sodertorn University College, Huddinge, SE-14157, SE-141 04, Swed.
SOURCE: Perkin 1 (2000), (16), 2609-2614
CODEN: PERKF9
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:310045
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The bisindolesuccinic acid Me ester I was obtained by an iodine-promoted coupling of the dianion II. The diester was converted to the N-benzylimide III, which was oxidatively cyclized to the indolo[2,3-a]pyrrolo[3,4-c]carbazol IV. The diester I could be directly transformed to the known indolocarbazole diester V via acid-induced intramol. cyclization in TFA. The same methodol. gave arcyriaflavin A from the succinimide VI.

IT **115684-55-4P 137467-08-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(coupling reactions of indole-3-acetic acid derivs., synthesis of arcyriaflavin A)

RN 115684-55-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)





RN 137467-08-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **137467-07-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(coupling reactions of indole-3-acetic acid derivs., synthesis of arcyriaflavin A)
RN 137467-07-3 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:549150 CAPLUS
DOCUMENT NUMBER: 131:165337
TITLE: Indole derivatives as cell death inhibitors
INVENTOR(S): Asakai, Rei; Sodeoka, Mikiko; Fujita, Mikako; Katoh, Miho
PATENT ASSIGNEE(S): Sagami Chemical Research Center, Japan
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9942100	A1	19990826	WO 1999-JP772	19990222

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

09622815

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9925486	A1	19990906	AU 1999-25486	19990222
EP 1057484	A1	20001206	EP 1999-905260	19990222

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRIORITY APPLN. INFO.:

JP 1998-40147	A	19980223
JP 1998-40148	A	19980223
JP 1998-162118	A	19980610
JP 1998-162119	A	19980610
WO 1999-JP772	W	19990222

GI



I

AB Cell death inhibitors, drugs, preservatives for cells, tissues and organs, and assay systems of cell death inhibitors contg., as the active ingredient, indole derivs. represented by general formula [I] or pharmaceutically acceptable salts thereof which are expected as usable as preventives and remedies for the progress of various diseases wherein cell death participates in the progress and exacerbation thereof.

IT **238734-45-7P 238734-46-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(indole derivs. as cell death inhibitors)

RN 238734-45-7 CAPLUS

CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-1-methyl- (9CI) (CA INDEX NAME)



RN 238734-46-8 CAPLUS
CN 2,5-Pyrrolidinedione, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-4-(1H-indol-3-yl)-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:426247 CAPLUS
DOCUMENT NUMBER: 131:157870
TITLE: Conformational Control in the Rebeccamycin Class of Indolocarbazole Glycosides
AUTHOR(S): Gilbert, Eric J.; Chisholm, John D.; Van Vranken, David L.
CORPORATE SOURCE: Department of Chemistry, The University of California, Irvine, CA, 92697-2025, USA
SOURCE: Journal of Organic Chemistry (1999), 64(15), 5670-5676
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Indolocarbazole glycosides are balanced between two conformations: a "closed" conformation contg. a cyclic hydrogen bond between the indolocarbazole NH and the pyranose oxygen and an "open" conformation in which the indolocarbazole NH is hydrogen bonded to solvent. The open conformation never has a commanding advantage, even in DMSO, but in nonpolar environments the cyclic conformation predominates.
IT **222632-24-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and conformational control in the rebeccamycin class of indolocarbazole glycosides)
RN 222632-24-8 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-1-methyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:414220 CAPLUS
DOCUMENT NUMBER: 131:257739
TITLE: Indolocarbazoles: potent, selective inhibitors of human cytomegalovirus replication
AUTHOR(S): Slater, Martin J.; Cockerill, Stuart; Baxter, Robert; Bonser, Robert W.; Gohil, Kam; Gowrie, Clare; Robinson, J. Edward; Littler, Edward; Parry, Nigel; Randall, Roger; Snowden, Wendy
CORPORATE SOURCE: Glaxo Wellcome Medicines Research Centre, Stevenage, SG1 2NY, UK
SOURCE: Bioorganic & Medicinal Chemistry (1999), 7(6), 1067-1074
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB In a search for new, safer anti-HCMV agents, the natural product Arcyriaflavin A was found to be a potent inhibitor of HCMV replication in cell culture. A series of analogs (sym. indolocarbazoles) was synthesized to investigate structure-activity relationships in this series against a range of herpes viruses (HCMV, VZV, HSV1, and 2). This identified a no. of novel, selective and potent inhibitors of HCMV, 12,13-dihydro-2,10-difluoro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-(6H)-dione (I) being the best example (IC50 = 40 nM, therapeutic index > 1450). Compds. described in this series were generally poor inhibitors of protein kinase C .beta.II, and no correlation was found between the ability to inhibit HCMV and the enzyme PKC.

IT **137467-07-3 137467-08-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(indolocarbazoles: potent, selective inhibitors of human cytomegalovirus replication)
RN 137467-07-3 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 137467-08-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:218066 CAPLUS
DOCUMENT NUMBER: 130:282271
TITLE: A Caveat in the Application of the Exciton Chirality Method to N,N-Dialkyl Amides. Synthesis and Structural Revision of AT2433-B1
AUTHOR(S): Chisholm, John D.; Golik, Jerzy; Krishnan, Bala; Matson, James A.; Van Vranken, David L.
CORPORATE SOURCE: Department of Chemistry, University of California, Irvine, CA, 92697, USA
SOURCE: Journal of the American Chemical Society (1999), 121(15), 3801-3802
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal

09622815

LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Utilizing a Mannich cyclization/glycosylation route for the synthesis of indolo-carbazole glycosides and re-examn. of stereo-assignment using CD Cotton effects, the authors propose a revision of the abs. stereochem. of the amino-sugar ring of antibiotic AT2433-B1 (I), and by analogy, -A1, -A2, and -B2 members of the family. The abs. stereochem. of the amino-sugar was originally assigned as 3R, 4R by application of the exciton chirality method to a dibenzoyl deriv., from methanolysis of AT2433A1, based on the neg. chirality of the exciton couple. Independent synthesis of the pyranoside (II) gave a product with pos. chirality, opposite that predicted from amino-alcs. with the same abs. configuration. Mol. modeling studies indicated only a small energy difference in amide conformations of II, leading to opposite Cotton effects in the CD spectrum for E and Z amides; the overall resulting CD spectra depends on the relative population of conformers and the degree to which the two chromophores interact in each conformer, leading to either pos. or neg. chirality depending on which conformer dominated the CD spectrum.

IT **222632-24-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of in the synthesis and structural revision of AT2433-B1)

RN 222632-24-8 CAPLUS

CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-1-methyl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:496561 CAPLUS
DOCUMENT NUMBER: 129:202825
TITLE: A New, Efficient Method for the Synthesis of Bisindolylmaleimides
AUTHOR(S): Faul, Margaret M.; Winneroski, Leonard L.; Krumrich, Christine A.
CORPORATE SOURCE: Chemical Process Research and Development Division,

09622815

Lilly Research Laboratories A Division of Eli Lilly and Company, Indianapolis, IN, 46285-4813, USA
SOURCE: Journal of Organic Chemistry (1998), 63(17), 6053-6058
CODEN: JOCEAH; ISSN: 0022-3263
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:202825

AB Both sym. and unsym. bisindolylmaleimides were prepd. by reaction of indole-3-acetamides with Me indolyl-3-glyoxylates using a soln. of KOBu-t in THF. The reaction is successful in the presence of a variety of functional groups (H, alkyl, Oh, NMe2, OTr).

IT **212200-73-2P 212200-74-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of bisindolylmaleimides)

RN 212200-73-2 CAPLUS
CN 2,5-Pyrrolidinedione, 3-hydroxy-3,4-di-1H-indol-3-yl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 212200-74-3 CAPLUS
CN 2,5-Pyrrolidinedione, 3-hydroxy-3,4-di-1H-indol-3-yl-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:147304 CAPLUS
DOCUMENT NUMBER: 128:192545
TITLE: Synthesis of bisindolylmaleimides as potent PKC

09622815

inhibitors
INVENTOR(S): Faul, Margaret Mary; Winneroski, Leonard L., Jr.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807693	A1	19980226	WO 1997-US14771	19970822
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 825190	A1	19980225	EP 1997-306438	19970822
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
AU 9741570	A1	19980306	AU 1997-41570	19970822
AU 716840	B2	20000309		
BR 9711363	A	19990817	BR 1997-11363	19970822
CN 1228082	A	19990908	CN 1997-197361	19970822
US 5990319	A	19991123	US 1997-917052	19970822
NZ 334030	A	20000825	NZ 1997-334030	19970822
JP 2000516632	T2	20001212	JP 1998-510991	19970822
US 5948907	A	19990907	US 1998-81252	19980519
US 6133452	A	20001017	US 1999-234722	19990121
NO 9900832	A	19990413	NO 1999-832	19990222

PRIORITY APPLN. INFO.:
US 1996-24120P P 19960823
US 1997-917052 A 19970822
WO 1997-US14771 W 19970822

OTHER SOURCE(S): CASREACT 128:192545; MARPAT 128:192545
GI



I



II



III

arteries
AUTHOR(S): Fabre, S.; Prudhomme, M.
CORPORATE SOURCE: Laboratoire de Chimie Organique Biologique, Universite, Blaise Pascal, Aubiere, F-63177, Fr.
SOURCE: Archives Internationales de Pharmacodynamie et de Therapie (1995), 329(3), 397-404
CODEN: AIPTAK; ISSN: 0003-9780
PUBLISHER: Heymans Institute of Pharmacology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects of 12 compds., structural related to the indolocarbazole bacterial metabolite staurosporine, on caffeine-induced contractions in rabbit renal arteries were studied. Eight of these compds. are effective protein kinase C inhibitors, the others are inactive towards the enzyme. The results show a link between the protein kinase C inhibitory activity and the inhibition of vascular smooth muscle contraction. However, a strong inhibition of protein kinase C is required to observe the vasorelaxant effect.

IT **169211-30-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(vasorelaxant effects of indolocarbazole and bis-indole protein kinase C inhibitors on rabbit renal arteries)

RN 169211-30-7 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(hydroxymethyl)-3,4-di-1H-indol-3-yl- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:776459 CAPLUS
DOCUMENT NUMBER: 123:193410
TITLE: Antimicrobial activities of indolocarbazole and bis-indole protein kinase C inhibitors. II. Substitution on maleimide nitrogen with functional groups bearing a labile hydrogen
AUTHOR(S): Pereira, Elisabete Rodrigues; Fabre, Serge; Sancelme, Martine; Prudhomme, Michelle
CORPORATE SOURCE: Laboratoire de Chimie Organique Biologique, Universite Blaise Pascal, Aubiere, 63177, Fr.
SOURCE: Journal of Antibiotics (1995), 48(8), 863-8
CODEN: JANTAJ; ISSN: 0021-8820
PUBLISHER: Japan Antibiotics Research Association
DOCUMENT TYPE: Journal
LANGUAGE: English

AB K-252c derivs., structurally related to the potent protein kinase C

inhibitor staurosporine and substituted on the imide nitrogen with a function group bearing a labile hydrogen (hydroxymethyl, amino, hydroxy), were synthesized. Their in vitro inhibitory potencies towards protein kinase C and protein kinase A showed that N-hydroxymethyl and N-hydroxy substitution, unlike alkyl substitution, can provide efficient protein kinase C inhibitors. The antimicrobial activities of these new compds. against Streptomyces chartreusis and Streptomyces griseus, Bacillus cereus, Escherichia coli, Candida albicans and Botrytis cinerea were examd. They prove to be inactive against E. coli and two fungi. The results suggest that there is no link between in vitro inhibition of protein kinase C and inhibition of growth and sporulation of the two Streptomyces tested. Unlike indolocarbazole maleimides, bis-indole maleimides are active against the two Streptomyces species.

IT **152540-67-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(antimicrobial activities of indolocarbazole and bis-indole protein kinase C inhibitors)

RN 152540-67-5 CAPLUS

CN 2,5-Pyrrolidinedione, 1-(hydroxymethyl)-3,4-di-1H-indol-3-yl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1995:772989 CAPLUS

DOCUMENT NUMBER: 123:167736

TITLE: Microtetraspora strain for preparation of indolopyrrolocarbazole derivatives

INVENTOR(S): Kojiri, Katsuhisa; Suzuki, Hajime; Kondo, Hisao; Suda, Hiroyuki

PATENT ASSIGNEE(S): Banyu Pharmaceutical Co., Ltd., Japan

SOURCE: U.S., 9 pp. Cont.-in-part of U.S. Ser. No. 68, 097.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5437996	A	19950801	US 1993-166364	19931214
PL 172609	B1	19971031	PL 1992-316369	19921127
TW 390907	B	20000521	TW 1993-82110519	19931211

US 5591842	A	19970107	US 1994-255980		19940608
US 5589365	A	19961231	US 1995-381286		19950131
US 5643760	A	19970701	US 1995-486640		19950607
PRIORITY APPLN. INFO.:			US 1992-981070	A2	19921124
			JP 1992-353623	A	19921214
			JP 1993-53035	A	19930218
			US 1993-68097	A2	19930528
			JP 1991-341916	A	19911129
			JP 1992-69269	A	19920218
			JP 1992-257306	A	19920901
			WO 1992-JP1549	W	19921127
			US 1993-166364	A2	19931214

OTHER SOURCE(S): MARPAT 123:167736
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process is disclosed for prepn. of compds. represented by (I), wherein X1 and X2 each independently represent H, a halogen, amino, mono- or di-lower alkylamino, OH, lower alkoxy, aralkoxy, carboxyl, lower alkoxycarbonyl, lower alkanoyloxy, or lower alkyl group and R is H, an amino, formylamino, lower alkanoylamino, mono- or di-lower alkylamino, OH, lower alkoxy, aralkoxy, aralkyl, or lower alkyl group, which comprises cultivating a microorganism having an ability to glycosylate a compd. represented by (II) wherein X1, X2, and R have the same meanings as defined above, in a nutrient medium contg. II, and recovering the formed I from the culture medium. The resultant compds. I have excellent antitumor activity.

IT **167411-61-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of and dichlorodicyanobenzoquinone reaction with)

RN 167411-61-2 CAPLUS

CN 2,5-Pyrrolidinedione, 3,4-bis(6-hydroxy-1H-indol-3-yl)-1-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	1995:35271 CAPLUS
DOCUMENT NUMBER:	122:5286
TITLE:	Antimicrobial activities of indolocarbazole and bis-indole protein kinase C inhibitors

09622815

AUTHOR(S): Sancelme, Martine; Fabre, Serge; Prudhomme, Michelle
CORPORATE SOURCE: Laboratoire Chimie Organique Biologique, Universite Blaise Pascal, Aubiere, 63177, Fr.
SOURCE: Journal of Antibiotics (1994), 47(7), 792-8
CODEN: JANTAJ; ISSN: 0021-8820
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The antimicrobial activities of twenty-two substances structurally related to staurosporine (I), aglycon in the indolocarbazole and bis-indole series were examd. against Streptomyces chartreusis and Streptomyces griseus, Bacillus cerus, Escherichia coli, Candida albicans and Botrytis cinerea. Inhibition of sporulation was examd. also on the two Streptomyces species. Unlike literature reports for efficient protein kinase inhibitors, staurosporine and K-252a, no evident correlation could be found either between protein kinase inhibitory potencies and inhibition of sporulation of the Streptomyces species or protein kinase between inhibitory potencies and growth of all microorganisms tested. A weak activity against C. albicans was obsd. for the chloro-indolocarbazole compds. as already reported for structurally related substances from the cyanobacterium Tolypothrix tjipanasensis.

IT **137467-08-4**
RL: BIOL (Biological study)
(antimicrobial activity of and protein kinase C insensitivity to)

RN 137467-08-4 CAPLUS

CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



09622815

IT **152540-67-5**
RL: BIOL (Biological study)
(antimicrobial and protein kinase C-inhibiting activities of)
RN 152540-67-5 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(hydroxymethyl)-3,4-di-1H-indol-3-yl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1994:128295 CAPLUS
DOCUMENT NUMBER: 120:128295
TITLE: Protein kinase C inhibitors; structure-activity relationships in K252c-related compounds
AUTHOR(S): Fabre, Serge; Prudhomme, Michelle; Rapp, Maryse
CORPORATE SOURCE: Lab. Chim. Org. Biol., Univ. Blaise Pascal, Aubiere, 63177, Fr.
SOURCE: Bioorganic & Medicinal Chemistry (1993), 1(3), 193-6
CODEN: BMECEP; ISSN: 0968-0896
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB K252c (I)-related compds. were prepd. with different framework flexibilities and different functions (imide, amide and amide-alc.) on the nonindole heterocycle. The inhibitory activities towards protein kinase C and protein kinase A were compared.
IT **137467-08-4P 152540-67-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and protein kinase C-inhibiting activity of, structure in relation to)

RN 137467-08-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 152540-67-5 CAPLUS
CN 2,5-Pyrrolidinedione, 1-(hydroxymethyl)-3,4-di-1H-indol-3-yl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1994:106760 CAPLUS
DOCUMENT NUMBER: 120:106760
TITLE: Antiviral bis(indolyl)pyrrolidones
INVENTOR(S): Slater, Martin John; Cockerill, George Stuart; Littler, Edward
PATENT ASSIGNEE(S): Wellcome Foundation Ltd., UK
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9318765	A1	19930930	WO 1993-GB570	19930319

W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,

BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG

AU 9337613	A1	19931021	AU 1993-37613	19930319
EP 630241	A1	19941228	EP 1993-906708	19930319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07504673	T2	19950525	JP 1993-516378	19930319

PRIORITY APPLN. INFO.: GB 1992-6056 19920320
GB 1992-6809 19920327
WO 1993-GB570 19930319

OTHER SOURCE(S): MARPAT 120:106760

GI



I

AB The title compds. I [R1 = H, alkylcarbonyl, arylcarbonyl, CO2H, carboxylate ester, (un)substituted C1-8 alkyl, (un)substituted C1-8 alkenyl, etc.; R2, R3 = H, arylcarbonyl, alkylcarbonyl, CHO, CO2H, carboxylate ester, H, etc.; R4, R5 = H, (un)substituted C1-6 alkyl, (un)substituted C3-7 cycloalkyl, (un)substituted aryl, etc.; R6, R7 = H, (un)substituted C1-6 alkyl, CN, NO2, halogen, methylenedioxy etc.; R13, R14 = H, alkoxy, aryloxy, alkylthio, arylthio, etc.; R13R14 = :O], useful in the treatment of coxsackie virus, (no data), varicella zoster virus (no data), Epstein-Barr virus (no data), cytomegalovirus, etc., are prepd. and I-contg. formulations presented. Thus, 3,4-bis(1H-2-methylindol-3-yl)-2,5-dihydro-1-phenylmethyl-1H-pyrrolo-2,5-dione was reacted in EtOH with Zn amalgam, producing cis-3,4-bis(2-methyl-1H-indol-3-yl)-1-phenylmethylsuccinimide (II). II demonstrated 50% viral inhibitory concn. against human cytomegalovirus-infected MRC5 (human embryonic lung) cells of 8.5 .mu.M.

IT **115684-55-4 137467-08-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antiviral activity of)

RN 115684-55-4 CAPLUS

CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)





RN 137467-08-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **152538-08-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and antiviral activity of)
RN 152538-08-4 CAPLUS
CN 2,5-Pyrrolidinedione, 3,4-bis(2-methyl-1H-indol-3-yl)-1-(phenylmethyl)-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:576457 CAPLUS
DOCUMENT NUMBER: 119:176457
TITLE: New fluorescent probes for protein kinase C. Synthesis, characterization, and application
AUTHOR(S): Chen, Chii Shiarng; Poenie, Martin
CORPORATE SOURCE: Dep. Zool., Univ. Texas, Austin, TX, 78712, USA
SOURCE: Journal of Biological Chemistry (1993), 268(21), 15812-22
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Fluorescent derivs. of the bisindolylmaleimide inhibitors of protein kinase C (PKC) were synthesized and tested with respect to their inhibitory potency, specificity, and usefulness as fluorescent cytol. stains for PKC. Several of the fluorescent bisindolylmaleimide derivs. (fim-1, fim-2, and rim-1) acted as ATP-competitive catalytic site inhibitors and retained much of the potency and specificity of the parental compd. The R6-C1 and the PKC.beta.1-overexpressing R6-PCK3 cell lines were used for testing fim-1 and rim-1 as cytol. strains for PKC. Comparisons showed that the R6-PCK3 cells stained much more brightly than R6-C1 cells. When R6-PKC3 cells were treated with the phorbol ester phorbol 12-myristate 13-acetate (PMA) for 30 min, staining with fim-1 or anti-PKC.beta.1 revealed a dramatic translocation of PKC to the cell periphery. When R6-PKC3 cells were exposed to PMA for 24 h to down-regulate PKC, cytoplasmic staining was drastically reduced. Staining patterns obtained with an antibody specific for PKC.beta.1 and with fim-1 were remarkably similar except for mitochondrial staining, which was only seen with fim-1. A closer examn. of the mitochondrial staining showed that mitochondria convert from filamentous to punctate shapes and cluster around the nucleus when cells are treated with PMA. This punctate morphol., perinuclear clustering, and staining with fim-1 persists when PKC is down-regulated. Overall, these results indicate that fim-1 and rim-1 can serve as useful fluorescent probes for PKC. The mitochondrial staining may be due to a PKC isoform resistant to downregulation.

IT **150234-70-1P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and spectral properties of)
RN 150234-70-1 CAPLUS
CN Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-5-carboxamide, 3',6'-bis(acetyloxy)-N-[3-[3-[4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-3-pyrrolidinyl]-1H-indol-1-yl]propyl]-3-oxo-, diacetate (9CI) (CA INDEX NAME)

09622815

CM 1

CRN 150234-69-8
CMF C49 H38 N4 O10



CM 2

CRN 64-19-7
CMF C2 H4 O2



L4 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1992:41230 CAPLUS
DOCUMENT NUMBER: 116:41230
TITLE: Inhibitors of protein kinase C. 1. 2,3-bisarylmaleimides
AUTHOR(S): Davis, Peter D.; Hill, Christopher H.; Lawton, Geoffrey; Nixon, John S.; Wilkinson, Sandra E.; Hurst, Steven A.; Keech, Elizabeth; Turner, Susan E.
CORPORATE SOURCE: Roche Prod. Ltd., Welwyn Garden City/Herts., AL7 3AY, UK
SOURCE: Journal of Medicinal Chemistry (1992), 35(1), 177-84
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of novel inhibitors, i.e., maleimides I (R = H, Me; R1 = (un)substituted indolyl, (un)substituted Ph, naphthyl, benzo[b]thien-3-yl, benzo[b]furan-3-yl, 3-pyrrolyl) of protein kinase C (PKC) is described. These maleimides were derived from the structural lead provided by the indolocarbazoles, staurosporine and K252a. Optimum activity required the imide NH, both carbonyl groups, and the olefinic bond of the maleimide ring. Bisindolylmaleimides were the most active and the potency of these was improved by a chloro substituent at the 5-position of one indole ring (IC50 0.11 .mu.M). In a series of (phenylindolyl)maleimides, nitro deriv. I (R = Me, R1 = 2-O2NC6H5) was most active (IC50 0.67 .mu.M). Naphthalene compd. I (R = Me, R1 = 1-naphthyl) and benzothiphene compd. I (R = Me, R2 = benzo[b]thien-3-yl) showed greater than 100-fold selectivity for inhibition of PKC over the closely related cAMP-dependent protein kinase.

IT **137467-07-3P 137467-08-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and protein kinase C inhibiting activity of)

RN 137467-07-3 CAPLUS

CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 137467-08-4 CAPLUS

CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1991:674290 CAPLUS
DOCUMENT NUMBER: 115:274290
TITLE: The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
AUTHOR(S): Toullec, Dominique; Pianetti, Pascal; Coste, Herve; Bellevergue, Patrice; Grand-Perret, Thierry; Ajakane, Myriam; Baudet, Valerie; Boissin, Patrick; Boursier, Eric; et al.
CORPORATE SOURCE: Cent. Rech., Lab. Glaxo, Les Ulis, 91951, Fr.
SOURCE: Journal of Biological Chemistry (1991), 266(24), 15771-81
CODEN: JBCHA3; ISSN: 0021-9258
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Staurosporine is the most potent inhibitor of protein kinase C (PKC) described in the literature with a half-maximal inhibitory concn. (IC50) of 10 nM. Nevertheless, this natural product is poorly selective when assayed against other protein kinases. To obtain specific PKC inhibitors, a series of bisindolylmaleimides has been synthesized. Structure-activity relationship studies allowed the detn. of the substructure responsible for conferring high potency and lack of selectivity in the staurosporine mol. Several aminoalkyl bisindolylmaleimides were found to be potent and selective PKC inhibitors (IC50 values from 5 to 70 nM). Among these compds. GF 109203X has been chosen for further studies aiming at the characterization of this chem. family. GF 109203X was a competitive inhibitor with respect to ATP (Ki = 14 nM) and displayed high selectivity for PKC as compared to five different protein kinases. The potency and specificity of GF 109203X was further detd. in 2 cellular models: human platelets and Swiss 3T3 fibroblasts. GF 109203X efficiently prevented PKC-mediated phosphorylations of an Mr = 47,000 protein in platelets and of an Mr = 80,000 protein in Swiss 3T3 cells. In contrast, in the same models, the PKC inhibitor failed to prevent PKC-independent phoshorylations. GF 109203X inhibited collagen- and .alpha.-thrombin-induced platelet aggregation as well as collagen-triggered ATP secretion. However, ADP-dependent reversible aggregation was not modified. In Swiss 3T3 fibroblasts, GF 109203X reversed the inhibition of EGF binding induced by phorbol 12,13-dibutyrate and prevented [3H]thymidine incorporation into DNA, only when this was elicited by growth promoting agents which activate PKC. These results illustrate the potential of GF 109203X as a tool for studying the involvement of PKC in signal transduction pathways.

IT **137592-36-0**
RL: BIOL (Biological study)
(protein kinase C of human and lab. animal inhibition by, structure in relation to)
RN 137592-36-0 CAPLUS

CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl- (9CI) (CA INDEX NAME)





L4 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1988:473718 CAPLUS
DOCUMENT NUMBER: 109:73718
TITLE: Coupling of indoleacetic acid trianion or methyl indoleacetic acid dianion. A biomimetic approach to indolocarbazole alkaloids
AUTHOR(S): Bergman, J.; Pelcman, B.
CORPORATE SOURCE: Dep. Org. Chem., Royal Inst. Technol., Stockholm, S-100 44, Swed.
SOURCE: Tetrahedron Letters (1987), 28(38), 4441-4
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 109:73718
GI



I



II



III



I



II



III

AB The bisindolesuccinic acid ester I was obtained as a mixt. of diastereomers by iodine promoted coupling of the dianion of Me 3-indoleacetate or via the trianion of 3-indoleacetic acid. The diester was converted to the N-benzylimide II which was oxidatively cyclized to the indolo[2,3-a]pyrrolo[3,4-c]carbazole compd. III.

IT **115684-55-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and oxidn. of)

RN 115684-55-4 CAPLUS

CN 2,5-Pyrrolidinedione, 3,4-di-1H-indol-3-yl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)





US 1028677709P1

Creation date: 10-17-2003
Indexing Officer: ALIEU - ANDY LIEU
Team: 1600PrintWorkingFolder
Dossier: 10286777

Legal Date: 10-16-2003

No.	Doccode	Number of pages
1	CTFR	9
2	1449	1
3	FWCLM	1
4	SRFW	1

Total number of pages: 12

Remarks:

Order of re-scan issued on .....